{"filings":[{"id":582039,"accession_number":"0001161697-26-000128","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-05-21T20:11:32+00:00","items":["5.07"],"status":"ready","headline":"KORU Medical shareholders approve all proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with over 97% of votes cast.","Shareholders approved amendment to 2024 Omnibus Equity Incentive Plan to increase share pool.","Advisory say-on-pay vote passed with ~99.6% of votes cast.","Advisory vote on frequency set at every one year (24.9M votes for 1-year).","Ratification of Cherry Bekaert as auditor for FY 2026 approved with ~99.9% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98378,"accession_number":"0001161697-26-000107","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q1 revenue $11.8M (+22% YoY); net loss improves to $0.8M; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $11.8M, up 22% YoY; domestic core +11.7%, international core +35.2%, pharma services +166%.","Gross profit $7.2M (+20% YoY); gross margin 61.5% vs 62.8% on tariff costs and production timing.","Net loss improved 31% to $0.8M ($0.02 diluted EPS) from $1.2M ($0.03) in prior year.","Cash $8.8M; cash usage $0.1M in Q1. Reiterates FY2026 revenue $47.5-50.0M, positive adjusted EBITDA & cash flow.","Submitted 510(k) for Freedom Infusion System with deferoxamine; two pharma collaborations advanced to Phase III."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":11764624.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98377,"accession_number":"0001161697-26-000086","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"KORU Medical amends HSBC credit facility, extends maturities and lowers rate floor","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment extends $5M revolver maturity from Dec 31, 2026 to Mar 30, 2028.","Term loan interest-only period extended to Jun 30, 2027, with possible further extension to Dec 31, 2027 upon EBITDA milestones.","Term loan maturity extended to Dec 1, 2029; interest rate floor reduced to 5.50% from 6.50%.","Adjusted quick ratio covenant removed; replaced by 12-month liquidity covenant when drawn or positive trailing 3-month Adjusted EBITDA.","Company has not drawn on the $10M total facility and has no obligation to do so."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113802,"accession_number":"0001161697-26-000055","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Linda Tharby to retire June 2026; Adam Kalbermatten named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tharby retires as CEO effective June 30, 2026; will serve as advisory employee through Dec 31, 2026.","Kalbermatten appointed President March 15, 2026, and becomes CEO July 1, 2026.","Kalbermatten's base salary: $450K through June, then $525K; 2026 bonus target 80%; LTI target $1.25M.","One-time PSU award of $1.25M to Kalbermatten effective July 1, 2026 with performance goals (75% revenue growth, 25% market cap).","Tharby's equity: some PSUs/RSUs continue vesting through Dec 31, 2026; all remaining unvested awards forfeited thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113801,"accession_number":"0001161697-26-000051","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical reports 22% FY2025 revenue growth; positive adjusted EBITDA; initiates FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenue $10.9M (+23% YoY); FY2025 net revenue $41.1M (+22% YoY).","International Core revenue grew 80% in FY2025; Domestic Core grew 11%.","FY2025 net loss narrowed 57% to $2.6M ($0.06 loss per share); positive adjusted EBITDA of $0.6M.","Cash and cash equivalents $8.9M at Dec 31, 2025; used only $0.7M cash in FY2025.","FY2026 guidance: net revenue $47.5–$50.0M (15–22% growth); positive adjusted EBITDA and positive cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113800,"accession_number":"0001161697-26-000038","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"KORU Medical amends bylaws to enhance stockholder nomination procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board unanimously adopted amended bylaws effective Feb 5, 2026.","Enhances procedural mechanics and disclosure for stockholder nominations and proposals.","Requires compliance with universal proxy Rule 14a-19 and additional disclosures from nominating stockholders.","Changes advance notice deadline for director nominations when board size increases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113799,"accession_number":"0001161697-26-000027","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical prelim Q4 revenue $10.9M (+23% YoY); FY revenue $41.1M (+22% YoY); positive op cash flow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 net revenue $10.9M, up 23% YoY; full year net revenue $41.1M, up 22% YoY.","Ending cash balance $8.9M; positive cash flow from operations in Q4 and for full year.","Submitted 510(k) for Freedom Infusion System for use with Phesgo, expanding into oncology.","Company plans to release final 2025 results and 2026 guidance in early March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":41127366.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130210,"accession_number":"0001161697-25-000426","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"KORU Medical restates manufacturing/supply pact with Command Medical through 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, effective Jan 1, 2024.","Agreement expires Dec 31, 2026, with automatic one-year renewals unless either party opts out.","Covers manufacturing of subassemblies, needle sets, and tubing per KORU specifications and purchase orders.","Includes pricing, payment, rebates, purchase commitments, warranty, IP, and confidentiality terms.","Either party may terminate on uncured material breach (45-day cure) or bankruptcy/insolvency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130209,"accession_number":"0001161697-25-000371","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q3 revenue $10.4M (+27% YoY), raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenues $10.4M, up 27% YoY; core business (domestic + international) $9.8M, up 30%.","Net loss narrowed 51% to $0.8M; positive adjusted EBITDA of $0.09M vs. $(0.4M) prior year.","International core revenue surged 229.6% to $3.7M; domestic core declined 5.0%.","Raising FY2025 revenue guidance to $40.5-41.0M (from $39.5-40.5M); gross margin guidance reiterated at 61-63%.","Ending cash balance $8.5M; generated $0.4M cash in Q3; reiterating positive full-year cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":30232038.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146769,"accession_number":"0001161697-25-000216","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q2 revenue up 21% to record $10.2M; raises FY 2025 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net revenue of $10.2 million, +21% YoY; Core revenue $9.3M (+19%), PST $0.9M (+42%).","Adjusted EBITDA positive $0.3M vs ($0.4M) in prior year; net loss narrowed to $0.2M from $1.3M.","Raises FY 2025 revenue guidance to $39.5-$40.5M (prev. $38.5-$39.5M); gross margin guidance 61%-63% reaffirmed.","Cash balance $8.1M at Q2-end; reiterated positive operating cash flow for FY 2025.","Adam Kalbermatten named Chief Commercial Officer; FDA 510(k) submitted for a rare disease biologic drug."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":19829875.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165198,"accession_number":"0001161697-25-000173","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"KORU Medical Systems shareholders elect all director nominees at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven nominees elected; votes 'for' ranged from 23.5M to 23.9M of 23.95M cast (excl. broker non-votes).","Advisory vote on executive compensation passed: 23.2M for, 0.7M against, 81.6K abstain.","Ratification of Cherry Bekaert LLP as independent auditor for 2025: 36.9M for, 9.6K against.","Total shares voted: 36,949,703; broker non-votes were 12,997,325 on director and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165197,"accession_number":"0001161697-25-000168","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical reports record Q1 revenue of $9.6M, up 18% YoY; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core revenue (Domestic + International) grew 21% YoY to $9.4M; International up 35.6%.","Gross margin improved 50 bps to 62.8%; gross profit $6.0M, up 19%.","Net loss narrowed; adjusted EBITDA improved to ($0.2M) from ($0.9M) prior year.","FY2025 revenue guidance raised to $38.5-39.5M from $38-39M; gross margin guidance reiterated at 61-63%.","Plans to submit two drugs for FDA 510(k) clearance with Freedom Infusion System by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":9635075.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165196,"accession_number":"0001161697-25-000142","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"KORU Medical CCO resigns; FY2025 revenue guidance reiterated at $38-39M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth Miller resigned as Chief Commercial Officer effective April 3, 2025, to become CEO at a non-competing firm.","Rob Cannon (VP of Sales, North America) will lead Core commercial operations until a permanent CCO is named.","Company retained an executive search firm to find a new CCO.","KORU Medical reaffirmed FY2025 revenue guidance of $38.0-$39.0 million, unchanged from March 12 call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165195,"accession_number":"0001161697-25-000140","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"KORU Medical amends loan agreement, extends credit facility maturity to Dec 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment extends $5M revolving credit facility maturity to Dec 31, 2026; term loan interest-only period to Oct 1, 2026.","Adjusted Quick Ratio covenant reduced from 1.50:1.00 to 1.25:1.00; company has not drawn on facility.","Amendment with HSBC Ventures USA Inc. effective March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182879,"accession_number":"0001161697-25-000099","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical reports record Q4 revenue of $8.8M (+23% YoY); issues 2025 guidance $38-39M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $8.8M (+23% YoY); full year $33.6M (+18% YoY).","Q4 gross margin 62.9% (+260 bps); full year 63.4% (+480 bps).","Net loss improved to $1.6M (Q4) and $6.1M (full year); adjusted EBITDA loss narrowed.","Cash $9.6M at Dec 31; Q4 cash flow positive $0.8M; 2025 guidance: revenue $38-39M, gross margin 61-63%, operational cash flow positive.","Novel Therapies segment renamed Pharma Services and Clinical Trials (PST), effective Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182878,"accession_number":"0001161697-25-000050","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"KORU Medical reports record Q4 revenue $8.9M (+23% YoY); positive cash flow in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary full-year 2024 net revenue of $33.7M, up 18% YoY; Q4 revenue $8.9M, up 23% YoY.","Ending cash balance $9.6M; Q4 generated positive cash flow of $0.8M.","Full-year cash burn $1.9M, a 67% improvement over prior year.","CEO cites U.S. market share gains, international expansion, and progress on new drug therapy labeling."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":33646463.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199463,"accession_number":"0001161697-24-000440","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q3 revenue $8.2M (+17% YoY); raises FY 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $8.2M, up 17% YoY; gross margin 63.4%, up 140 bps from 62.0%.","Core revenue $7.6M (+11% YoY); novel therapies $0.6M (+276% YoY).","Net loss $1.6M ($0.03 diluted EPS); adjusted EBITDA loss $0.4M.","Raises FY 2024 revenue guidance to $32.75-33.25M (15-17% growth) from $32.0-32.5M.","Raises FY 2024 gross margin guidance to 62-63%; year-end cash guidance >$8.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":24807864.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215499,"accession_number":"0001161697-24-000365","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"KORU Medical Systems adopts LTIP; grants up to 434,489 PSUs plus RSUs and options to execs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LTIP approved; equity awards granted to CEO Tharby (63,872 RSUs, 127,660 PSUs, 140,950 options) and other named execs.","PSUs vest based on FY2026 revenue achievement (0%-150% of target) with stock price modifier (0.5x-1.5x); max shares 434,489.","RSUs and options vest over 4 years; option exercise price $2.33 per share.","Kenneth Miller (CCO) gets base salary increase to $385,000 and bonus potential up to 60% of base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215498,"accession_number":"0001161697-24-000335","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q2 revenue record $8.4M, up 22%; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenues of $8.4M, a 22% YoY increase; core business grew 20% driven by SCIg market growth and share gains.","Gross margin expanded to 65% from 56.1% YoY, a 890bps improvement; gross profit up 41% to $5.5M.","Net loss improved to $1.0M ($0.02 per share) from $2.5M loss ($0.05 per share) in Q2 2023; adjusted EBITDA loss narrowed to $0.4M.","Raised FY2024 revenue guidance to $32.0-$32.5M (12-14% growth) and gross margin guidance to 61-62%.","Cash balance $10.5M; quarterly cash usage $0.3M; reaffirmed cash flow breakeven in Q4 2024 and positive cash in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":16627887.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215497,"accession_number":"0001161697-24-000314","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"KORU Medical appoints Christopher Pazdan as COO, eliminates CTO role held by Brian Case","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Pazdan appointed Chief Operating Officer, effective July 18, 2024, from SVP Operations.","Brian Case's position as Chief Technology Officer eliminated, termination effective September 16, 2024.","Pazdan's base salary set at $350,000, annual bonus up to 50% of base salary; severance includes 12 months base salary plus health premiums.","Pazdan joined KORU in 2021, has over 20 years experience in medical technology QA/regulatory affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234836,"accession_number":"0001161697-24-000250","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Koru Medical dismisses MMQ as auditor, engages Cherry Bekaert","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed McGrail Merkel Quinn & Associates (MMQ) effective June 3, 2024.","Engaged Cherry Bekaert LLP as independent auditor for fiscal year ending December 31, 2024.","MMQ reports for FY 2023 and 2022 had no adverse opinion, disclaimer, or modifications.","No disagreements or reportable events occurred with MMQ during the past two years or interim period.","MMQ provided a letter to the SEC agreeing with the company's disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234835,"accession_number":"0001161697-24-000230","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Koru Medical Systems reports 2024 annual meeting results; all proposals passed","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected all 7 director nominees: Fletcher, Cascella, French, Manko, Matin, Tharby, Wholihan.","Advisory compensation vote approved: 26.4M for, 0.5M against, 0.2M abstain.","Ratified McGrail Merkel Quinn as independent auditor for 2024 (38.3M for, 11.5K against).","Approved 2024 Omnibus Equity Incentive Plan (26.1M for, 0.8M against, 0.2M abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234834,"accession_number":"0001161697-24-000225","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q1 revenue up 11% to $8.2M; gross margin expands 620bps to 62.3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $8.2M, +10.9% YoY; Core business grew 13.6%, driven by 63% International increase.","Gross margin 62.3% vs 56.1% YoY, aided by outsourced manufacturing and US site consolidation.","Net loss narrowed to $1.9M ($0.04/share) from $2.4M; Adj EBITDA loss improved to $0.9M.","Reaffirmed FY2024 revenue guidance of $31.2-32.2M (10-13% growth); gross margin 59-61% expected.","Added a novel oncology therapy collaboration, bringing total to 16, with 3 YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":8197798.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234833,"accession_number":"0001161697-24-000196","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"KORU Medical wins EU notified body appeal, CE certification continues uninterrupted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BSI had recommended against continued certification after March 2024 audit nonconformance.","Appeal upheld April 8, 2024; no suspension or interruption of EU product sales.","Products remain certified, marketed, and sold in EU; proceeds through routine BSI assessment.","CEO Linda Tharby cites swift team response and positive BSI interaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252685,"accession_number":"0001161697-24-000140","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","9.01"],"status":"ready","headline":"KORU Medical reports Q4 rev $7.2M, FY net loss $13.7M; guides 2024 rev $31.2-32.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenues $7.2M (-2% YoY); gross margin improved to 60.3% (+470bps).","Full year net loss $13.7M ($0.30/sh) includes $6M non-cash tax valuation allowance; Adjusted EBITDA ($6.0M) vs ($6.1M) prior year.","Full year 2024 revenue guidance $31.2-32.2M (10-13% growth); gross margin 59-61%; cash flow breakeven in Q4 2024.","Entered $10M credit facility with HSBC ($5M revolver + $5M term loan; undrawn); warrant for 76,104 shares at $2.12.","EU notified body BSI recommended against continued certification; appeal filed; mgmt expects minimal revenue impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}